Veeva Systems (VEEV) Stock Overview
Provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
VEEV passed our risk checks.
VEEV Community Fair Values
Create NarrativeSee what 275 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Veeva Systems
31.2% undervalued intrinsic discount
AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability
View narrativeJO
Updated 27 Aug
Veeva Systems Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$263.75 |
| 52 Week High | US$310.50 |
| 52 Week Low | US$148.05 |
| Beta | 0.97 |
| 1 Month Change | 8.65% |
| 3 Month Change | 72.05% |
| 1 Year Change | -5.49% |
| 3 Year Change | 29.80% |
| 5 Year Change | -11.70% |
| Change since IPO | 609.77% |
Recent News & Updates
Narrative Update • Sep 03
VEEV: Elevated AI Optimism Will Pressure CRM Expectations Going Forward
Analysts have lifted their fair value estimate for Veeva Systems from $165.00 to about $227.65, reflecting higher assumed revenue growth and a richer future P/E multiple, partly supported by recent price target increases tied to expected billings strength, CRM wins, and perceived insulation from AI disruption. Analyst Commentary Recent Street research on Veeva Systems highlights a generally constructive view, with several firms lifting price targets and pointing to strengths in CRM, subscription growth and the company’s positioning around AI.Seeking Alpha • Aug 27
Veeva Systems: A Combination Of Growth, Margins, And Financial Strength
Summary Veeva Systems is rated a buy, supported by durable double-digit revenue growth, expanding profitability, and a robust, debt-light balance sheet. VEEV's recurring subscription model drives high margins—Q1 FY2027 saw 75% GAAP gross margin and 86.4% subscription gross margin, with continued product adoption fueling growth. Management raised FY2027 guidance and targets a $6 billion revenue run rate by 2030, with Q2 revenue expected to exceed guidance. Valuation risk has moderated, with VEEV now trading at 44x trailing and 38x forward earnings as the company grows into its premium multiple. Read the full article on Seeking AlphaRecent updates
Narrative Update • Sep 03
VEEV: Elevated AI Optimism Will Pressure CRM Expectations Going Forward
Analysts have lifted their fair value estimate for Veeva Systems from $165.00 to about $227.65, reflecting higher assumed revenue growth and a richer future P/E multiple, partly supported by recent price target increases tied to expected billings strength, CRM wins, and perceived insulation from AI disruption. Analyst Commentary Recent Street research on Veeva Systems highlights a generally constructive view, with several firms lifting price targets and pointing to strengths in CRM, subscription growth and the company’s positioning around AI.Seeking Alpha • Aug 27
Veeva Systems: A Combination Of Growth, Margins, And Financial Strength
Summary Veeva Systems is rated a buy, supported by durable double-digit revenue growth, expanding profitability, and a robust, debt-light balance sheet. VEEV's recurring subscription model drives high margins—Q1 FY2027 saw 75% GAAP gross margin and 86.4% subscription gross margin, with continued product adoption fueling growth. Management raised FY2027 guidance and targets a $6 billion revenue run rate by 2030, with Q2 revenue expected to exceed guidance. Valuation risk has moderated, with VEEV now trading at 44x trailing and 38x forward earnings as the company grows into its premium multiple. Read the full article on Seeking Alpha
Narrative Update • Aug 27
Veeva Just Had a Great Quarter. That's Exactly Why I'm Not Buying More.
Revenue beat. Earnings beat.
Narrative Update • Aug 20
VEEV: AI Demand And CRM Wins Will Support Balanced Future Returns
Veeva Systems' analyst-derived fair value estimate has moved from $245.48 to $251.43 as analysts factor in Street research pointing to steadier normalized billings growth, customer interest in AI and CRM offerings, and mixed but generally constructive views on long term demand. Analyst Commentary Recent Street views on Veeva Systems show a wide range of opinions on execution, growth durability, and how current pricing lines up with perceived fundamentals.Narrative Update • Jul 13
VEEV: AI Disruption Fears Will Pressure Core CRM Durability
Veeva Systems' updated analyst price target has been reduced from about $232.80 to $165.00. Analysts cite slightly lower modeled revenue growth, a lower assumed future P/E multiple, and ongoing debates around AI disruption and competitive pressure in core CRM offerings, despite steady Q1 execution and continued AI product development.New Narrative • Jul 03
AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability
Investors often look for artificial intelligence winners in the obvious places: semiconductors, hyperscalers, and general-purpose software platforms. But some of the most durable AI opportunities may sit in far less glamorous places—inside the regulated workflows where a mistake is not merely inconvenient, but potentially delays a drug trial, a regulatory submission, or a therapy reaching patients.
Narrative Update • Jun 29
VEEV: AI Execution And CRM Wins Will Drive Future Upside
Veeva Systems’ analyst fair value estimate has been reset lower from about $380 to roughly $338, reflecting Street price target cuts as analysts weigh solid Q1 execution against AI disruption risk, competitive CRM questions, and a shift toward more measured profit margin and P/E assumptions. Analyst Commentary Street research on Veeva Systems presents a mixed but generally constructive picture, with many firms recalibrating price targets while still pointing to solid Q1 execution, ongoing demand in health technology, and emerging AI and CRM catalysts as key elements in their valuation work.Analysis Article • Jun 20
Veeva Systems (VEEV) Stock Could Be 38% Undervalued After Fed Driven Pullback
Veeva Systems (VEEV) shares fell after the Federal Reserve held its benchmark rate and signaled a more restrictive stance, as higher Treasury yields weighed on software sector valuations, including healthcare and life sciences platforms. See our latest analysis for Veeva Systems. At around US$153.30, Veeva Systems’ recent share price weakness has been broad based, with a 1 day share price return of 1% and a year to date share price return down 30.16%, while the 1 year total shareholder return...Narrative Update • Jun 15
VEEV: AI Execution And CRM Wins Will Support Future Multiple Reacceleration
Narrative Update The analyst price target for Veeva Systems in this framework is updated from about $263 to about $245, as analysts balance solid Q1 execution and raised guidance with AI disruption risk, CRM competition from Salesforce, and questions around the quality and mix of recent upside, particularly in services. Analyst Commentary Recent research on Veeva Systems reflects a split view, with most analysts acknowledging solid Q1 execution and raised guidance, but debating how much weight to give AI disruption risk, CRM competition, and the quality of services driven upside when thinking about valuation, execution, and long term growth.Narrative Update • Jun 01
VEEV: AI Moat And CRM Commitments Will Support Future Multiple Reacceleration
Narrative Update The analyst price target for Veeva Systems has been trimmed by about $2 to $262.68 as analysts factor in compressed software multiples, while largely maintaining their underlying growth, margin, and P/E assumptions. Analyst Commentary Recent research on Veeva Systems clusters around strong reported execution in Q4, tempered by valuation resets tied to compressed software multiples and longer term questions around AI and CRM competition.Narrative Update • May 11
VEEV: AI Moat And CRM Commitments Will Support Premium Multiple
Veeva Systems' updated analyst price target edges lower to about $264 from roughly $265, as analysts keep their broadly positive take on the company's recent Q4 results but adjust valuation assumptions to reflect compressed software multiples and ongoing debates around AI, R&D growth, and CRM stability. Analyst Commentary Recent research on Veeva reflects a mix of optimism about execution in Q4 and caution around valuation and longer term growth drivers.Narrative Update • Apr 25
VEEV: AI Moat And Subscription Resilience Will Support Premium Multiple
Analysts have trimmed the Veeva Systems price target slightly, with the model fair value moving from about $270.93 to $264.46, as modestly lower assumed future P/E multiples more than offset largely unchanged growth and margin expectations. Analyst Commentary Recent Street research around Veeva Systems shows a split view, with many firms trimming price targets while still pointing to solid execution and specific areas of uncertainty that could influence the valuation over time.Narrative Update • Apr 08
VEEV: AI And Subscription Resilience Will Support Premium Software Multiple
Analysts trimmed the blended Veeva Systems price target by aligning with sector wide software multiple compression, even as they point to strong Q4 execution, resilient subscription growth, and an emerging AI and product pipeline as key longer term supports. Analyst Commentary Recent Street research around Veeva Systems reflects a mix of optimism on execution and growth, alongside more cautious views on competitive risk, AI impact, and valuation.Narrative Update • Mar 25
VEEV: AI Adoption In R&D Workflows Will Support Durable Premium Outlook
Analysts have adjusted their price targets on Veeva Systems into a roughly $190 to $317 range, generally trimming prior targets by tens of dollars as software valuation multiples compress, even after what they describe as solid Q4 results and broadly constructive longer term fundamentals. Analyst Commentary Recent research paints a mixed but generally constructive picture for Veeva Systems, with most firms trimming price targets while still pointing to solid execution and durable fundamentals.Narrative Update • Mar 11
VEEV: AI Adoption And CRM Commitments Will Support Durable Premium Outlook
We are trimming our Veeva Systems fair value estimate to $270.93 from $302.60, as analysts broadly reset price targets in response to sector wide software multiple compression and slightly more measured assumptions for revenue growth, margins, and future P/E multiples, despite generally solid Q4 results and guidance. Analyst Commentary Street research on Veeva Systems has become more mixed, with many firms cutting price targets while still acknowledging solid Q4 execution and robust profitability.Narrative Update • Feb 25
VEEV: AI Execution And CRM Stability Will Support Durable Premium Outlook
Our fair value estimate for Veeva Systems has edged down from $308.63 to $302.60. This reflects a series of reduced Street price targets as analysts weigh maturing products, competitive pressures, software sentiment, and the balance of growth opportunities against current valuation.Narrative Update • Feb 10
VEEV: Roche Commitment And CRM Retention Will Support Durable Premium Outlook
Our analyst fair value estimate for Veeva Systems has been trimmed slightly to $308.63. This reflects a modest reset in Street price targets as analysts balance concerns about slower growth in maturing products and competitive pressure with ongoing strengths in areas like Crossix, AI adoption, and large CRM wins such as Roche.New Narrative • Jan 28
Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside
Catalysts About Veeva Systems Veeva Systems provides cloud based software, data and consulting services to life sciences companies across commercial, R&D and manufacturing functions. What are the underlying business or industry changes driving this perspective?Narrative Update • Jan 27
VEEV: Roche Rollout And CRM Retention Will Support Durable Premium Outlook
The analyst price target embedded in our Veeva Systems model edges slightly lower to about US$310 from roughly US$311. This reflects a blend of more cautious views on growth and competitive pressure, along with offsetting positive views on durable margins, CRM customer retention, and newer areas such as Crossix and early AI traction.Narrative Update • Jan 12
VEEV: Roche Expansion And CRM Migrations Will Support Durable Premium Outlook
Analysts have trimmed their fair value estimate for Veeva Systems by about US$1 to US$310.98, reflecting modest adjustments to discount rate and growth assumptions while still pointing to what they see as durable growth drivers such as pharma CRM migrations, broader Vault adoption and newer areas like Crossix and AI. Analyst Commentary Recent Street research on Veeva Systems reflects a mix of optimism and caution, with differing views clustering around the durability of growth in CRM and Vault, the timing of pharma migrations, and how current valuation stacks up against execution and contract wins.Narrative Update • Dec 19
VEEV: Roche Commitment And CRM Migrations Will Likely Sustain Premium Outlook
Analysts have modestly trimmed their blended price target for Veeva Systems to about $312 from roughly $321, reflecting a slightly higher discount rate and lower implied future multiple, even as they highlight accelerating CRM migrations, including Roche's global Vault CRM rollout, and improving long term growth and margin expectations. Analyst Commentary Street research remains broadly constructive on Veeva Systems, with recent target changes reflecting a recalibration of software multiples rather than a material shift in company specific fundamentals.Analysis Article • Dec 03
Veeva Systems' (NYSE:VEEV) Performance Is Even Better Than Its Earnings Suggest
Investors were underwhelmed by the solid earnings posted by Veeva Systems Inc. ( NYSE:VEEV ) recently. We have done...Narrative Update • Nov 11
VEEV: Continued Momentum And New Commitments Will Likely Sustain Premium Outlook
Analysts have significantly raised their price targets on Veeva Systems, with recent updates moving targets as high as $380. They cite the company's strong sales growth prospects and solid momentum, driven by accelerating CRM customer commitments and new partnerships.Narrative Update • Oct 27
Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters
Veeva Systems' analyst price target saw a significant increase, rising by more than $80 to reflect higher expectations for sales growth and ongoing customer commitments. Analysts cited the company’s strengthening position in CRM and positive momentum across key pharma relationships.Narrative Update • Oct 13
IQVIA Resolution And Embedded AI Will Expand Digital Healthcare Cloud
Narrative Update on Veeva Systems: Analyst Price Target Revision Analysts have raised their fair value estimate for Veeva Systems to approximately $321 per share, up by nearly $4. They cited stronger than expected sales momentum, driven by new major customer commitments and continued growth in key business segments.Narrative Update • Aug 29
Data Cloud Expansion And AI Efficiencies Will Drive Future Success
Analysts have raised their price target for Veeva Systems to $314.71, citing strong Q2 “beat and raise” results, momentum in both Commercial and R&D segments, successful Vault CRM rollouts with major pharma clients, and ongoing market share gains in life sciences CRM. Analyst Commentary Bullish analysts highlighted Veeva's strong “beat and raise” Q2 results, with both subscription and services revenues growing solidly year-over-year, driven by performance in both Commercial and R&D technology segments.Seeking Alpha • Apr 17
Veeva Systems: Substantially Overvalued As Growth Slows
Summary Veeva Systems is overvalued, trading at frothy levels despite only ~10% growth, and facing a potential slowdown in 2025; I recommend a sell rating. The company excels in the life sciences vertical with unique solutions but its ambitious revenue targets (doubling revenue by 2030) may be tough to achieve organically. Valuation multiples are high at ~10 EV/FY26 revenue and ~30x FY26 P/E, well above a number of peers - some of which are growing even faster than Veeva. Read the full article on Seeking AlphaSeeking Alpha • Mar 19
Veeva Systems: Staying Buy Rated As VEEV Is Executing Well
Summary I reaffirm my buy rating on Veeva Systems due to strong 4Q25 results, driven by R&D growth and positive Vault CRM adoption traction. VEEV's revenue grew 14% y/y to $721 million, beating expectations, with significant margin improvements and a strong balance sheet. Vault CRM added 20 new customers, with multiple top 20 pharma commitments expected in 2025, signaling positive transition progress. Data Cloud segment shows strong momentum, with new initiatives like Pulse expected to drive further CRM adoption and growth. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Veeva Systems: Solid Q4 With Margin Expansion
Summary I reiterate my “Strong Buy” rating on Veeva Systems Inc. with a one-year target price of $275 per share due to strong CRM migration and margin improvement. Veeva reported 14.3% revenue growth and 28.7% adjusted operating profit growth, driven by robust CRM adoption and billing growth. Management's guidance for FY26 includes $3.04-$3.055 billion in revenue, with anticipated 12% revenue growth despite high-interest rate challenges. I foresee continued margin expansion and revenue growth recovery to 16% by FY27 for VEEV, supported by CRM migration and easing capital funding challenges. Read the full article on Seeking AlphaShareholder Returns
| VEEV | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 1.1% | 4.1% | 0.5% |
| 1Y | -5.5% | -17.5% | 12.0% |
Return vs Industry: VEEV exceeded the US Healthcare Services industry which returned -17.5% over the past year.
Return vs Market: VEEV underperformed the US Market which returned 12% over the past year.
Price Volatility
| VEEV volatility | |
|---|---|
| VEEV Average Weekly Movement | 7.0% |
| Healthcare Services Industry Average Movement | 10.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VEEV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VEEV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7,928 | Peter Gassner | www.veeva.com |
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics.
Veeva Systems Inc. Fundamentals Summary
| VEEV fundamental statistics | |
|---|---|
| Market cap | US$42.89b |
| Earnings (TTM) | US$1.01b |
| Revenue (TTM) | US$3.46b |
42.1x
P/E Ratio12.3x
P/S RatioIs VEEV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VEEV income statement (TTM) | |
|---|---|
| Revenue | US$3.46b |
| Cost of Revenue | US$865.88m |
| Gross Profit | US$2.59b |
| Other Expenses | US$1.58b |
| Earnings | US$1.01b |
Last Reported Earnings
Jul 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.27 |
| Gross Margin | 74.96% |
| Net Profit Margin | 29.34% |
| Debt/Equity Ratio | 0% |
How did VEEV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/17 02:25 |
| End of Day Share Price | 2026/09/17 00:00 |
| Earnings | 2026/07/31 |
| Annual Earnings | 2026/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Veeva Systems Inc. is covered by 47 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Vruwink | Baird |
| Saket Kalia | Barclays |
| "Saket Kalia | Barclays |